Contrast Media Market-Overview
The launch of new products in the medical sector is projected to motivate the Contrast Media Market. The market’s report is efficiently analyzed as per MRFR, which provides outlooks for the global markets. The market is estimated to demonstrate expansion with a 3.5% CAGR by 2025.
The amplified occurrence of serious illnesses is estimated to promote the contrast media market share in the forecast period. Moreover, the availability of cutting-edge medical equipment is anticipated to propel the contrast media market in the impending period.
Segmental Analysis
The segmental overview of the contrast media market is conducted on the basis of type, form, procedures, applications, route of administration and region. The procedures segment of the contrast media market consists of X-ray/computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI). The application segment of the contrast media market consists of oncology, cardiovascular disease, gastrointestinal disorders, and neurological disorders. The type segment of the contrast media market consists of gadolinium-based contrast media, microbubble contrast media, iodinated contrast media, and barium-based contrast media. The form segment of the contrast media market consists of tablets, liquid, powder, and paste. The region segment of the contrast media market consists of the Asia Pacific, the Middle East, the Americas, Europe, and Africa. The route of administration segment of the contrast media market consists of has been segmented into oral, rectal, and injectable.
Browse Complete Toc :https://www.marketresearchfuture.com/reports/contrast-media-market-1284
Detailed Regional Analysis
The regional review of the contrast media market consists of the Asia Pacific, the Middle East, the Americas, Europe, and Africa. The Americas contrast media market is estimated to overshadow the global market due to the growing demand for medical imaging, the analysis of numerous health disorders and people ailing from spinal injury, intestinal diseases, brain problems, cancer, and other diseases necessitating medical imaging. The European contrast media market is anticipated to control the second chief position in the global market. The collective healthcare spending, growing economy, and the incidence of many medical device businesses in this region are driving the contrast media market growth. The Asia Pacific regional market is anticipated to be the fastest increasing region due to the growing old population with spinal fractures, problems, and health conditions. The swelling patient group is boosting the demand for medical imaging, which lifts the contrast media market in the Asia Pacific region.
Competitive Analysis
The improved spending by businesses on research and development is estimated to spur the market’s advance further. The market is projected to see a turbulent growth phase ahead as the return to normalcy may occur in a staggered manner. Many countries are lifting or imposing lockdown measures intermittently, which may lead to slower market progress. The major corporations in the market are estimated to engage in strategies that will fortify and enhance their global position through mergers and new product launches. Governments worldwide are expected to amplify as they are motivated to get the economic recovery back on track. The investment in developing e-commerce channels as well as the distribution network is predicted to accelerate global growth. Several countries’ easing of regulatory measures is predicted to promote the market’s resurgence in the upcoming years. The advanced utilization of raw materials effectively is predicted to create avenues for development in the forecast period. The focus on sustainability-related goals is estimated to streamline the next phase of development in the global market.
The well-known players in the contrast media market are NANOSCAN IMAGING (US), Bayer AG (Germany), Lantheus Medical Imaging Inc. (US), Bracco Diagnostic Inc. (US), Guerbet Group (France), DAIICHI (Japan), Jodas Expoim (India), Magnus Health (US), Spago Nanomedical AB (Germany), GE Healthcare (US), and Taejoon Pharm (Korea).
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/1044
Industry Updates:
Mar 2021 A cooperative research team effort has developed a nanoparticle-based MRI contrast agent, named SAIO, abbreviation for Supramolecular Amorphous-like Iron Oxide recently. The particle is 5 nanometers in size, which is about 1,500 times tinier than the microvascular width. This lets it pass around blood vessels in the body. The SAIO is a distinct nanoparticle that contains a polysaccharide core prepared primarily with dextran cross-linked with other particles. This core is then covered with an iron oxide surface to give it paramagnetic properties at room temperature.
Dec 2020 The academics at Harvard Medical School (HMS) and Massachusetts General Hospital (MGH) are progressing a substitute MRI contrast agent built on manganese, a vital component in human nutrition that is found in legumes, nuts, seeds, whole grains and leafy green vegetables that are easily handled and removed by the body. Manganese has magnetic properties comparable to those of gadolinium, but lacking gadolinium’s toxicity.
No comments:
Post a Comment